Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?

43Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Although upfront surgery has been the gold standard for pancreatic adenocarcinoma that is planned for resection, it should be compared with the alternative strategy of neoadjuvant therapy. Despite the many reports of the efficacy of neoadjuvant therapy, most of them were not comparative. Recently Prep-02/JSAP05 study clearly demonstrated the significant survival benefit of neoadjuvant chemotherapy over upfront surgery for pancreatic adenocarcinoma that is planned for resection. These findings opened a new chapter of neoadjuvant therapy. Ongoing trials are expected to confirm the evidence. This review summarizes the past, present, and future perspectives of neoadjuvant therapy and its optimization.

Cite

CITATION STYLE

APA

Motoi, F., & Unno, M. (2020, March 1). Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol? Annals of Gastroenterological Surgery. Wiley-Blackwell Publishing Ltd. https://doi.org/10.1002/ags3.12311

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free